Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767857 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
NCT01767857 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 643 participants.
The verdict
NCT01767857, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.
Interventions
- DRUG Placebo
- DRUG Xilonix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2013-03-31 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767857
The ClinicalTrials.gov registry entry for NCT01767857 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01767857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01767857 about?
NCT01767857 is a clinical study titled "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer". The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.
What is the current status of trial NCT01767857?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2013-03-31. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT01767857?
The interventions under investigation include: Placebo (DRUG), Xilonix (DRUG).
Who is sponsoring clinical trial NCT01767857?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.